Monthly Archives: April 2012

Is the FDA violating its own mandate to approve safe drugs?

Share Is the Food and Drug Administration violating its own mandate to approve safe drugs? That was the question that Donald Light, co-author of The Risk for Prescription Drugs and a long-time medical sociologist, posed at a talk yesterday at … Continue reading

Posted in antidepressants, biotech industry, clinical trials, continuing medical education, drug marketing, FDA, health care costs, medical devices, patient care, pharmaceutical industry, scientific misconduct, suicide rates, Uncategorized | Tagged , , , , , , , , , | 2 Comments

How drug companies continue to hide the true story of Tamiflu and other drugs from the American public

Share I’ve been reading Dr. David Healy’s new book, Pharmageddon, and while some of it may seem like old news, I was struck by his fresh analysis of how the pharmaceutical industry has turned the original purpose of clinical trials … Continue reading

Posted in antidepressants, antipsychotic drugs, clinical trials, drug marketing, FDA, health care costs, patient care, pharmaceutical industry, scientific misconduct | Tagged , , , , , , , , | 1 Comment